Limited efficacy of zonisamide in the treatment of refractory infantile spasms

Epilepsia Open

Brenda Asilnejad¹  Rajsekar R. Rajaraman¹  Matthew Ji¹  Haley Peters¹  Raman Sankar¹  Shaun A. Hussain¹  Mario Navarro¹  Jaeden Heesch¹ 

[1] Department of Pediatrics (Division of Pediatric Neurology) David Geffen School of Medicine and UCLA Mattel Children’s Hospital Los Angeles California;

关键词: epileptic spasms;    hypsarrhythmia;    West syndrome;   

DOI  :  10.1002/epi4.12381

来源: DOAJ

【 摘 要 】

Abstract A series of relatively small studies collectively suggest that zonisamide may be effective in the treatment of infantile spasms. Using a large single‐center cohort of children with infantile spasms, we set out to evaluate the efficacy and safety of zonisamide. We retrospectively identified all patients with infantile spasms who were treated with zonisamide at our center. For each patient, we recorded dates of birth, infantile spasms onset, response (if any), and most recent follow‐up. To quantify zonisamide exposure, we recorded daily dosage and patient weight at each sequential encounter so as to allow calculation of peak and weighted‐average weight‐based dosage. We identified 87 children who were treated with zonisamide, of whom 78 had previously been treated with hormonal therapy or vigabatrin. Peak and weighted‐average zonisamide dosage were 7.1 (interquartile range 3.6, 10.2) and 5.4 (interquartile range 3.0, 8.9) mg/kg/day, respectively. Whereas five (6%) patients exhibited resolution of epileptic spasms, only two (2%) patients exhibited video‐EEG confirmed resolution of both epileptic spasms and hypsarrhythmia (electroclinical response). Importantly, both electroclinical responders had not previously been treated with hormonal therapy or vigabatrin; in contrast, none of the 78 children with prior failure of hormonal therapy or vigabatrin subsequently responded to zonisamide. Zonisamide was well tolerated, and there were no deaths. This study suggests that zonisamide exhibits favorable tolerability but very limited efficacy among patients who do not respond to first‐line therapy.

【 授权许可】

Unknown